Jennifer Michaelson

Jennifer Michaelson has over 20 years of experience in the biopharmaceutical industry. Jennifer began their career in 1997 as a Post-doctoral fellow at Harvard Medical School. In 2002, they were hired by Biogen Idec as a Scientist II, eventually becoming a Principal Scientist. In 2012, they were a Consultant for Third Rock Ventures and Jounce Therapeutics. From 2013 to 2017, they were with Jounce Therapeutics, Inc., starting as an Executive Program Leader/Senior Director of Pharmacology and Preclinical Development and later becoming the Director of Tumor Immunology. In 2017, they were the Head of Biologics at Third Rock Ventures newco (Celsius Therapeutics, pre Series A funding). Jennifer is currently the Chief Development Officer and Chief Development Officer (Biologics) at Cullinan Oncology, as well as the Vice President of Preclinical Research and Early Development.

Jennifer Michaelson completed a Postdoctoral Fellowship at Harvard Medical School from 1997 to 2002. Prior to that, they obtained their PhD from the Albert Einstein College of Medicine from 1990 to 1996. Jennifer obtained their AB from Princeton University from 1986 to 1990.